actual cannabinoid content,” comes at a time when the cannabis industry continues to struggle with product claims and consistency as the industry matures.
“The proposed work will allow a direct comparison of product content to product labels, enabling an independent quantification of any systematic biases that may exist across product types or testing facilities,” Dr.
Over the course of three years, the project will involve 480 authentic cannabis products randomly selected and purchased from state licensed retail dispensaries.
The proposed work represents a novel collaboration between cannabis scientists at a Colorado University and MedPharm.
The company provides cannabis pharmaceutical-type products in a certified current Good Manufacturing Practices facility that includes cultivation, pre-formulation, formulation development, small scale commercial manufacturing, analytical method development and validation, routine quality control analysis and stability studies.